Introduction {#s1}
============

The community-associated methicillin resistant *Staphylococcus aureus* (CA-MRSA) worldwide epidemic is polyclonal, however several well characterized clones predominate in different regions of the world: Sequence type (ST) 8-IV \[2B\] (USA300) and ST1-IV \[2B\] (USA400) in North America [@pone.0043037-Tenover1], [@pone.0043037-McDougal1]; ST80-IV \[2B\] (European clone) in Europe [@pone.0043037-Vandenesch1], North Africa [@pone.0043037-Bekkhoucha1] and the Middle East [@pone.0043037-Udo1]; ST59-V \[5C2&5\] (Taiwan clone) in Taiwan [@pone.0043037-BoyleVavra1], ST30-IV \[2B\] (South West Pacific \[SWP\] CA-MRSA) in the Western Pacific [@pone.0043037-Collignon1], [@pone.0043037-Riley1] and ST772-MRSA-V \[5C2\] (Bengal Bay clone) in India and Bangladesh [@pone.0043037-Ellington1]. Transmission of these clones into other regions has occurred [@pone.0043037-Nimmo1], [@pone.0043037-Tristan1]. The occurrence of concurrent epidemics of CA-MRSA in many countries by different clones has been striking. Equally noteworthy are a number of common features of these epidemics, prominent among them the ability to cause severe infections in young otherwise healthy people and the carriage of *lukS-PV*/*lukF-PV* Panton Valentine Leukocidin (PVL) encoding genes by the organism.

In Australia the PVL - positive ST93-IV \[2B\], colloquially known as "Queensland CA-MRSA", has recently emerged to become the dominant CA-MRSA clone. First described in the early 2000s, ST93 is a singleton by MLST eBURST analysis and is therefore distinct from other *S aureus* clones [@pone.0043037-Munckhof1].

In the 2010 Australian Group for Antimicrobial Resistance (AGAR) Community *S aureus* Surveillance Programme (SAP10) ST93-IV \[2B\] accounted for 41.4% of all CA-MRSA, 27.6% of all MRSA and 4.9% of all *S aureus* community-onset infections (<http://www.agargroup.org/files/FED%20REPORT%20SAP210%20MRSA%20FINAL%20shrink.pdf>.). The mean age of patients with ST93-IV \[2B\] infections (31 years, median 25 years) was significantly lower (P\<0.0001) than the mean age of patients with PVL negative CA-MRSA infections (53 years; median 57 years).

ST93-IV \[2B\] is associated with skin infection and severe invasive infection including necrotizing pneumonia, deep-seated abscess, osteomyelitis, septic arthritis and septicaemia [@pone.0043037-Coombs1], [@pone.0043037-Peleg1], [@pone.0043037-Risson1]. Although ST93-IV \[2B\] has an apparent enhanced clinical virulence, the recently sequenced ST93-IV \[2B\] strain "JKD6159" has a relative paucity of recognizable virulence determinants [@pone.0043037-Chua1], [@pone.0043037-Chua2]. This strain however does contain genes encoding three important CA-MRSA virulence factors, Hla, PVL and α-type phenol soluble modulins (PSMs), and when compared to three other well-characterised Australian MRSA strains, ST1-IV \[2B\], ST30-IV \[2B\] and ST239-III \[3B\] and the epidemic North American strain, USA300, was shown to be the most virulent in two *in vivo* models [@pone.0043037-Chua2].

While predominately an Australian strain, ST93-IV \[2B\] has been reported in New Zealand, accounting for 5.1% of all MRSA referred to the Institute of Environmental Science and Research in 2010 (<http://www.surv.esr.cri.nz/PDF_surveillance/Antimicrobial/MRSA/aMRSA_2010.pdf>), and in the United Kingdom, [@pone.0043037-Ellington2], where many cases have epidemiological links to Australia.

In Western Australia (WA) ST93-IV \[2B\] was first identified in 2003 [@pone.0043037-Coombs2] and in SAP10 accounted for 28.8% of the state's CA-MRSA community-onset infections. In the mid 1990s *S aureus* screening of indigenous people living in WA remote communities demonstrated the most prevalent methicillin susceptible *S aureus* (MSSA) linage isolated was the PVL-positive ST93 MSSA clone [@pone.0043037-OBrien1]. Although seven CA-MRSA clones from genetically diverse backgrounds were identified in these communities, no ST93 MRSA was found during this time.

As Australia is a geographically large country with the majority of the population densely concentrated in a few major cities which are separated in many instances by vast desert areas, it is to be expected that different CA-MRSA clones will have evolved in different areas of Australia. To better understand the molecular epidemiology of ST93-IV \[2B\], the aim of this study was to analyse the genetic relatedness of *S. aureus* ST93 isolated throughout Australia over an extended period and to determine if the increased prevalence of ST93-IV \[2B\] has been due to the widespread transmission of a single strain of ST93-IV \[2B\] or has been due to multiple independent acquisitions of the SCC*mec* element into different strains of ST93 MSSA.

Materials and Methods {#s2}
=====================

Bacterial Strains and Identification {#s2a}
------------------------------------

Overall 58 ST93 *S. aureus* were included in the study. The 13 ST93-MSSA included four isolates from remote aboriginal communities in WA, isolated from 1995 to 2003; two isolates from the Northern Territory, isolated in 1992; five isolates from WA, isolated in 2008; and single isolates from Victoria, isolated in 2007, and Queensland, isolated in 2008. The 45 ST93-MRSA included 30 isolates from across Australia from the 2000 to 2008 AGAR Community onset *S. aureus* programs, and 15 isolates from WA from 2003 to 2009. *S. aureus* species and methicillin resistance was confirmed by the detection of *nuc* (thermostable extracellular nuclease) and *mecA* (methicillin resistance) genes by PCR as previously described [@pone.0043037-Costa1].

Susceptibility Testing {#s2b}
----------------------

An antibiogram was performed by disk diffusion on Mueller-Hinton agar according to the Clinical and Laboratory Standards Institute (CLSI) recommendations [@pone.0043037-CLSI1]. A panel of eight antimicrobial drugs was tested: erythromycin (15 µg), tetracycline (30 µg), trimethoprim (5 µg), ciprofloxacin (5 µg), gentamicin (10 µg), rifampin (5 µg), fusidic acid (10 µg), and mupirocin (5 µg). CLSI interpretive criteria [@pone.0043037-CLSI2] were used for all drugs except fusidic acid [@pone.0043037-CASFM1] and mupirocin [@pone.0043037-Finlay1].

PFG {#s2c}
---

Electrophoresis of chromosomal DNA was performed as previously described [@pone.0043037-OBrien2], using a contour-clamped homogeneous electric field (CHEF) DR III system (Bio-Rad Laboratories Pty Ltd). Chromosomal patterns were examined visually, scanned with a Quantity One device (Bio-Rad Laboratories Pty Ltd), and digitally analyzed using FPQuest (Bio-Rad Laboratories Pty Ltd). *S. aureus* strain NCTC 8325 was used as a reference strain.

MLST and *Spa* Typing {#s2d}
---------------------

Chromosomal DNA for MLST and *spa* typing was prepared using a DNeasy tissue kit (Qiagen Pty Ltd).

MLST was performed as previously described [@pone.0043037-Enright1]. The sequences were submitted to <http://www.mlst.net/where> an allelic profile was generated and an ST assigned.

*spa* typing, a DNA sequenced-based analysis of the protein A gene variable region was performed as previously described [@pone.0043037-Harmsen1] using the nomenclature as described on the Ridom website (<http://spa.ridom.de/>). Cluster analysis of *spa* sequences was performed using the spa typing plug-in tool of the BioNumerics software program (version 6.6; Applied Maths, Ghent, Belgium). The analysis compares and aligns sequences via an algorithm based on potential tandem *spa* repeat duplications, substitutions, and indels (the DSI model) [@pone.0043037-Benson1]. A minimum spanning tree (MST) was generated from the similarity matrix with the root node assigned to the sequence type with the greatest number of related types. The default software parameters were used for analysis with a bin distance of 1.0%. Thus, the distance between *spa* types of 99% to 100% similarity was 0, 98% to 99% similarity was assigned a distance of 1, etc., on the MST. For cluster analysis, only *spa* types separated by an MST distance of ≤1 (i.e., if they were ≥98% similar) were considered closely related and assigned to the same cluster.

DNA Microarray {#s2e}
--------------

Arrays and reagents were obtained from Alere Technologies, Jena Germany. The principle of the assay, related procedures, and a list of targets has been described previously [@pone.0043037-Monecke1], [@pone.0043037-Monecke2]. Target genes included species markers, markers for accessory gene regulator (*agr*) alleles and capsule types, virulence factors, resistance genes, staphylococcal superantigen-like/exotoxin-like genes (*set*/*ssl* genes) and genes encoding adhesion proteins and immune evasion factors. Probes for *mecA*, *ugpQ*, *xylR*, *kdp*, *ccr*'s, *mecI* and two probes for *mecR* were used for SCC*mec* typing.

SCC*mec* Typing {#s2f}
---------------

The strategy used for SCC*mec* typing was as previously described [@pone.0043037-Coombs3]. SCC*mec* nomenclature is used as proposed by the International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC) [@pone.0043037-Elements1]. Briefly, the structural type is indicated by a Roman numeral, with a lowercase letter indicating the subtype, and the *ccr* complex and the *mec* complex are indicated by an Arabic numeral and an uppercase letter respectively in parenthesis. Where there is an extra *ccr* element, this is indicated by "&" and an Arabic numeral designating the *ccr* type. When there is an extra *ccr* element present whose precise location is unknown it is indicated by an "&" and *ccr* number outside the parentheses.

PVL {#s2g}
---

PCR for the detection of PVL determinants was performed as previously described [@pone.0043037-Fey1].

PVL Phage Identification {#s2h}
------------------------

PCRs were performed to detect the six PVL-encoding phages (ΦSa2MW, ΦSa2958, ΦPVL, Φ108PVL, ΦSLT and ΦSA2USA) as previously described [@pone.0043037-Ma1], [@pone.0043037-Boakes1].

Detection of Allelic Variations in *Luks-PV/lukF-PV* Genes {#s2i}
----------------------------------------------------------

Detection of single nucleotide polymorphisms (SNPs) in a defined region of the *lukS-PV/lukF-PV* genes were performed as previously described [@pone.0043037-Boakes1], [@pone.0043037-Wolter1]. Sequences obtained were compared to the proposed progenitor PVL gene in ΦSLT/ST30.

Quantification of *In vitro* LukF-PV Expression {#s2j}
-----------------------------------------------

PVL is a 2-component exotoxin and both LukS-PV and LukF-PV are required for activity. LukF-PV was measured instead of LukS-PV to obtain an anti-LukF-PV antibody with increased specificity of binding as there was more sequence divergence between *lukF-PV* and the orthologous 2-component *S. aureus* exotoxins compared to *lukS-PV*. To produce recombinant LukF-PV *lukF-PV* was PCR amplified using primers, forward 5′-CACCATGGCTCAACATATCACAC and reverse 5′-GCTCATAGGATTTTTTTCC. The resulting PCR product was then TOPO cloned into pENTR/SD/D-TOPO (Invitrogen). This plasmid was sequenced using M13 primers to confirm that the insert was present in the correct orientation without mutations. *lukF-PV* was subsequently cloned using an LR recombination reaction into the expression vector pET-DEST42 (Invitrogen) which introduced a C-terminal 6x-Histidine tag. This expression clone was used to transform Rosetta2 *E. coli* (Novagen). Soluble recombinant LukF-PV was produced by the Protein Production Unit, Monash University by growth of the expression strain in Auto Induction media at 28°C. The resulting recombinant LukF-PV was purified by Nickel purification followed by gel filtration and eluted in 100 mM NaP04, pH 7.4, 150 mM NaCl buffer. Aliquots were frozen and stored at −80°C. The concentration of recombinant LukF-PV was determined using the 2100 Bioanalyser P230 kit (Agilent).

Quantification of LukF-PV Expression {#s2k}
------------------------------------

Bacteria were grown in CCY media (3% yeast extract (Oxoid), 2% Bacto Casamino Acids (Difco), 2.3% sodium pyruvate (Sigma-Aldrich), 0.63% Na~2~HPO~4~, 0.041% KH~2~PO~4~, pH 6.7). Overnight cultures were diluted 1∶100 into fresh media and then incubated at 37°C with shaking (180 rpm) until stationary phase (OD600 ∼ 1.8). Culture supernatants were harvested by centrifugation and filter sterilized. The LukF-PV expression experiments were performed in at least duplicate for each *S. aureus* strain. Trichloroacetic acid was added to culture supernatants and incubated at 4°C overnight. Precipitates were then harvested by centrifugation, washed with acetone, air-dried and solubilized in a sample buffer containing 1.7% SDS and 1% 2-mercaptoethanol. The proteins were separated on 12% SDS-PAGE.

A peptide sequence specific to LukF-PV, HWIGNNYKDENRATHT was synthesized and HRP conjugated polyclonal chicken IgY raised against this peptide (Genscript). This antibody was used to detect LukF-PV with enhanced chemiluminescence. Images generated from the western blots were quantitated using GS800 Calibrated Densitometer and Quantity One (BioRad). 50 µg of recombinant LukF-PV was used as an internal standard on each gel, and was the positive control. Results observed with this standard were set to 1.0. All other results were shown as a ratio relative to this standard. RN4220 was used as a negative control.

*Dru* Typing {#s2l}
------------

Sequence analysis of the *mec*-associated *dru* region was performed as previously described [@pone.0043037-Goering1]. A cluster analysis of *dru* sequences was performed using the Polymorphic VNTR plug-in tool of the BioNumerics software program (version 6.6; Applied Maths, Ghent, Belgium). The analysis compares and aligns sequences via an algorithm based on potential tandem *dru* repeat duplications, substitutions, and indels (the DSI model) [@pone.0043037-Benson1]. A MST was generated from the similarity matrix with the root node assigned to the sequence type with the greatest number of related types. The default software parameters were used for analysis with a bin distance of 1.0%. Thus, the distance between *dru* types of 99% to 100% similarity was 0, 98% to 99% similarity was assigned a distance of 1, etc., on the MST. For cluster analysis, only *dru* types separated by an MST distance of ≤1 (i.e., if they were ≥98% similar) were considered closely related and assigned to the same cluster.

Control Strain {#s2m}
--------------

The sequenced ST93-IVa \[2B\] strain JKD6159 (NCBI GenBank Accession No. CP002114 and CP002115) was included in this study for comparison [@pone.0043037-Chua2].

Results {#s3}
=======

Susceptibility results, SCC*mec* typing together with a summary of the resistance genes, *spa* types (using the Ridom Nomenclature) and *dru* type are shown in [Table 1](#pone-0043037-t001){ref-type="table"}. Further characterisations are as follows:
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###### Characterisation of ST93 isolates.

![](pone.0043037.t001){#pone-0043037-t001-1}

  Region                Reference Number   Year    Specimen       Antibiogram        DNA Microarray Resistance Genotype    PFGE   MLST         *spa* Sequence         *Spa* Type   SCC*mec* type            dru Sequence             *Dru* Type   *lukS*/*lukF PV*
  -------------------- ------------------ ------ ------------ -------------------- -------------------------------------- ------ ------ ---------------------------- ------------ --------------- --------------------------------- ------------ ------------------
  **MSSA**                                                                                                                                                                                                                                       
  NT                        WBG 7735       1992    Unknown           Er^R^                *blaZ, blaI, blaR, ermC*          B      93    11-17-23-17-17-16-16-16-25     t4178           NA                       NA                                   POSITIVE
  NT                        WBG 7762       1992    Unknown           Er^R^                *blaZ, blaI, blaR, ermC*          A                  11-17-16-16-25           t4699           NA                       NA                                   POSITIVE
  Qld                         UQ40         2008    Unknown                                   *blaZ, blaI, blaR*             A             11-17-23-17-17-16-16-25        t202           NA                       NA                                   POSITIVE
  Vic                       DP 2039        2007    Unknown                                   *blaZ, blaI, blaR*             A      93     11-17-23-17-17-16-16-25        t202           NA                       NA                                   POSITIVE
  WA                         C229T         2003     Throat                                   *blaZ, blaI, blaR*             A            11-17-23-17-17-16-16-25-25     t5767           NA                       NA                                   POSITIVE
  WA                         N126W         2003     Hands            Er^R^                *blaZ, blaI, blaR, ermC*          C      93     11-17-23-17-17-16-16-25        t202           NA                       NA                                   POSITIVE
  WA                          W17S         1995      Skin                                    *blaZ, blaI, blaR*             C      93     11-17-23-17-17-16-16-25        t202           NA                       NA                                   POSITIVE
  WA                         Y113S         1996      Skin            Er^R^                *blaZ, blaI, blaR, ermC*          C             11-17-23-17-17-16-16-25        t202           NA                       NA                                   POSITIVE
  WA                        9506160A       2008     Blood                                    *blaZ, blaI, blaR*             A             11-17-23-17-17-16-16-25        t202           NA                       NA                                   POSITIVE
  WA                        9509712N       2008   Pleural Fl                                 *blaZ, blaI, blaR*             A               04-23-17-17-16-16-25        t6485           NA                       NA                                   POSITIVE
  WA                        9524093R       2008    Buttock                                   *blaZ, blaI, blaR*             A             11-17-23-17-17-16-16-25        t202           NA                       NA                                   POSITIVE
  WA                        9525206A       2008     Blood                                    *blaZ, blaI, blaR*             A             11-17-23-17-17-16-16-25        t202           NA                       NA                                   POSITIVE
  WA                        9529120L       2008      Heel            Er^R^                *blaZ, blaI, blaR, ermC*          A            11-17-23-17-17-16-16-25-25     t5767           NA                       NA                                   POSITIVE
  **MRSA**                                                                                                                                                                                                                                       
  ACT                       SAPTCH92       2000     Blood            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  ACT                       SAPTCH53       2008      Boil            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  NSW                      SAPRPAH96       2000      Eye          Ox^R^ Er^R^          *mecA, blaZ, blaI, blaR, ermC*       D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]                5a-2d-3b                  dt3b          POSITIVE
  NSW                       SAPWH23        2000     Wound            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]               5a-2d-3b-4e                dt4d          POSITIVE
  NSW                       SAPWH39        2000     Wound         Ox^R^ Er^R^             *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]               5a-2d-3b-4e                dt4d          POSITIVE
  NSW                       SAPWH61        2000     Wound            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  NSW                       SAPWH64        2000     Wound            Ox^R^             *mecA, blaZ, blaI, blaR, ermC*       E      93     11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  NSW                       SAPWH94        2000     Wound            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  NSW                       SAPWH71        2004     Blood            Ox^R^                *mecA, blaZ, blaI, blaR*          I      93       11-17-23-17-17-16-16        t6487       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          NEGATIVE
  NSW                      SAPCRGH95       2007     Blood            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-2a-2g-3b-4e       dt10g          POSITIVE
  NSW                      SAPRPAH21       2007     Sputum           Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  NSW                       SAPRPAH7       2008     Ulcer            Ox^R^             *mecA, blaZ, blaI, blaR, ermC*       D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
                                                                                                                                                                                                                                                      POSITIVE
  NSW                       SAPWH10        2008     Wound            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
                                                                                                                                                                                                                                                      POSITIVE
  NSW                       SAPWH53        2008     Wound      Ox^R^ Er^R^ Tmp^R^     *mecA, blaZ, blaI, blaR, msr(A)*      K      93        11-17-17-16-16-25          t1811       IVa \[2B\]                5a-2d-3b                  dt3b          NEGATIVE
  NT                        SAPRDH61       2006     Wound            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  NT                        SAPRDH27       2007     Thigh            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  NT                        SAPRDH2        2008      Leg             Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  Qld                       SAPRBH98       2000      Leg             Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  Qld                       SAPRBH12       2005     Blood            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  Qld                       SAPGCH3        2006    Abscess           Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  Qld                       SAPRBH14       2006     Wound            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  Qld                       SAPCBH10       2008    Aspirate          Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  Qld                       SAPGCH28       2008      Foot            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  Qld                       SAPRBH1        2008    Forearm           Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  SA                       SAPGPSA73       2000    Unknown           Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  SA                       SAPIMVS24       2006    Abscess           Ox^R^                *mecA, blaZ, blaI, blaR*          J             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  SA                       SAPIMVS31       2008      Boil            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  Vic                       SAPRCH74       2000     Wound            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]               5a-2d-3b-4e                dt4d          POSITIVE
  Vic                       SAPAH21        2008     Wound         Ox^R^ Te^R^          *mecA, blaZ, blaI, blaR, tetK*       D            11-17-23-17-17-16-16-16-25     t4178       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         16790         2003     Axilla           Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         16815         2005    Abscess           Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         15586         2008      Lip             Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]                5a-2d-3b                  dt3b          POSITIVE
  WA                         15587         2008      Nose         Ox^R^ Er^R^          *mecA, blaZ, blaI, blaR, ermC*       D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         16414         2008     Thigh            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]                5a-2d-3b                  dt3b          POSITIVE
  WA                         16475         2008      ETT             Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-4f-3a-2g-3b-4e       dt10i          POSITIVE
  WA                         17164         2008    Abscess           Ox^R^                *mecA, blaZ, blaI, blaR*          J             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         18158         2008     Wound            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]                5a-2d-3b                  dt3b          POSITIVE
  WA                         18385         2008      Shin            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         18418         2008      Nose            Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]                5a-2d-3b                  dt3b          POSITIVE
  WA                         20198         2008      Nose            Ox^R^                *mecA, blaZ, blaI, blaR*          H      93     11-17-23-17-17-16-16-25        t202       V \[5C2&5\]    5a-2d-4a-0-2d-5b-3a-2g-1c-4e-3e     dt11i          NEGATIVE
  WA                        SAPRPH48       2008     Wound            Ox^R^                *mecA, blaZ, blaI, blaR*          J      93     11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         16908         2009      Leg             Ox^R^            *mecA, blaZ, blaI, blaR, (dfrA)*      F      93     11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         17090         2009     Wound            Ox^R^             *mecA, blaZ, blaI, blaR, qacC*       G      93     11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         17195         2009      Nose         Ox^R^ Er^R^       *mecA, blaZ, blaI, blaR, ermC, qacC*    D      93     11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  WA                         20548         2009    Abscess           Ox^R^                *mecA, blaZ, blaI, blaR*          D             11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE
  **Control Strain**                                                                                                                                                                                                                             
  Vic                       JKD6159        2004     Blood            Ox^R^                *mecA, blaZ, blaI, blaR*          D      93     11-17-23-17-17-16-16-25        t202       IVa \[2B\]      5a-2d-4a-0-2d-5b-3a-2g-3b-4e       dt10a          POSITIVE

Regions: ACT, Australian Capital Territory; NSW, New South Wales; NT, Northern Territory, Qld, Queensland; SA, South Australia; Vic, Victoria; WA, Western Australia.

Antibiogram: Ox, oxacillin; Em, erythromycin; Te, tetracycline.

Resistance Genotype: *mecA*, alternate penicillin binding protein 2 gene; *blaZ*, beta lactamase gene; *blaI*, beta-lactamase repressor (inhibitor) gene; *blaR* beta-lactamase regulatory protein gene, *ermC*, erythromycin/clindamycin resistance gene; *msr(A)*, macrolide resistance gene; *tetK*, tetracycline resistance gene; *dfrA*, trimethoprim resistance gene; qacC quaternary ammonium compound resistance gene protein C.

PFGE, pulsed field gel electrophoresis; MLST, multilocus sequence type; SCCmec, staphylococcal cassette chromosome mec; *spa, Staphylococcus aureus* protein gene A; *dru*, the direct-repeat unit (*dru*) variable-number tandem repeat region adjacent to IS431 in SCC*mec.*

*lukF*/*lukS* PV, Panton Valentine leucocidin F and S component genes.

Molecular Typing {#s3a}
----------------

By PFGE the 58 isolates (13 MSSA and 45 MRSA) had ≥80% similarity with the sequenced JKD6159 strain ([Figure 1](#pone-0043037-g001){ref-type="fig"}). Eleven pulsotypes were identified. The MSSA isolates consisted of three pulsotypes, "A" -- "C" with 12 of the 13 isolates grouped into two closely related pulsotypes; "A" (9 isolates) and "C" (3 isolates). The MRSA isolates consisted of eight pulsotypes ("C" -- "K") with 39 of the 45 isolates grouped into two closely related pulsotypes; "D" (36 isolates) and "J" (3 isolates). The MSSA pulsotypes "A" and "C" and the MRSA pulsotypes "D" and "J" were 92% related; the difference presumably due to the insertion of the SCC*mec* type IVa \[2B\] element into an existing restriction fragment in the two MRSA pulsotypes. Single isolates of closely related MRSA pulsotypes "I" (SAPWH71) and "K" (SAPWH53) lacked a PVL-encoding phage. MRSA pulsotype "H" (20198) also lacked a PVL-encoding phage, however unlike the other MRSA, carried the SCC*mec* type V element with an additional *ccr* element \[5C2&5\]. The remaining MSSA and three MRSA isolates were classified into four unique pulsotypes (pulsotypes B, E, F, G).

![Dendrogram of the 58 pulsed-field gel electrophoresis patterns (PFGE) of ST93 (13 MSSA and 45 MRSA).\
Sequenced JKD6159 strain was used as the ST93 control. *S. aureus* strain NCTC 8325 was used as the reference strain.](pone.0043037.g001){#pone-0043037-g001}

Isolates representing each pulsotype were identified as ST93 by MLST.

Seven *spa* types were identified with the majority of isolates characterised as t202 (8/13 MSSA and 42/45 MRSA). The MST algorithm clustered the *spa* types into two significantly different groups; t202, t4178, t5767; t1811, t4699; plus t6487; and t6485 ([Figure 2](#pone-0043037-g002){ref-type="fig"}).

![Minimum spanning tree (MST) of the seven ST93 *spa* types.\
Cluster analysis was performed using the spa typing plug-in tool of the BioNumerics program. *spa* types separated by an MST distance of ≤1 (i.e., if they were ≥98% similar) were considered closely related and assigned to the same cluster. MSSA and MRSA *spa* types are designated in red and green print respectively. Pulsed-field gel electrophoresis (PFGE) pulsotypes and *dru* types (dt) are recorded for each *spa* type.](pone.0043037.g002){#pone-0043037-g002}

DNA Microarray {#s3b}
--------------

The β-lactamase operon (*bla*Z, *blaI*, *blaR*) was detected in all isolates ([Table 1](#pone-0043037-t001){ref-type="table"}). Apart from isolate 20198, the MRSA carried *mecA* as a part of the SCC*mec* type IVa \[2B\] element. Carriage of other resistance genes was infrequent and variable. Five of the MSSA were phenotypically erythromycin resistant and carried *ermC*. Of the five erythromycin resistant MRSA isolates, three carried *ermC* and one the staphylococcal *msr(A)* macrolide efflux protein gene. A macrolide resistance gene was not detected in one isolate that demonstrated phenotypic resistance (SAPWH39). Two *ermC* harbouring MRSA isolates were not phenotypically erythromycin resistant. A single MRSA isolate harboured the *tetK* tetracycline resistant gene (isolated in Victoria in 2008), and two MRSA isolates carried the quaternary ammonium compound resistance protein C (*qacC*) gene (isolated in WA in 2009).

The 58 isolates were *agr* group III and capsule type 8. Although the enterotoxin and *tst1* genes were absent from all isolates, the enterotoxin homologue ORF CM14 was present in 34 isolates (4 MSSA and 30 MRSA) ([Table S1](#pone.0043037.s001){ref-type="supplementary-material"}). All isolates carried the *hlb*, *hld* and *hlIII* hemolysin genes; the staphylokinase (*sak*), chemotaxis inhibitory protein (*chp*) and staphylococcal complement inhibitor (*scn*) genes; and the *aur*, *splA*, *sspA*, *sspB*, *sspP* protease genes. Although the gene for a biofilm-associated protein, *bap*, was absent, the biofilm operon icaACD was present in all isolates. Most isolates carried the leukocidin *lukX* and *lukY* genes, the *hl*, *hla* hemolysin genes and the *splE* protease genes.

The staphylococcal superantigen like or exotoxin-like genes (*set* or *ssl* genes) and genes encoding MSCRAMMS (microbial surface components recognizing adhesive matrix molecules) and the immune evasion factors were homogeneous and characteristic for ST93 ([Tables S2](#pone.0043037.s002){ref-type="supplementary-material"}, [S3](#pone.0043037.s003){ref-type="supplementary-material"}, S4 and [S5](#pone.0043037.s004){ref-type="supplementary-material"}).

Panton Valentine Leukocidin (PVL) {#s3c}
---------------------------------

Apart from three MRSA isolates (SAPWH71, SAPWH53 and 20198) the *lukS*-*PV/lukF*-*PV* genes were detected in all isolates by array hybridisation and PCR. All *lukS*-*PV/lukF*-*PV* positive isolates carried the PVL-encoding phage ΦSa2USA. Using the proposed progenitor PVL gene in ΦSLT/ST30 as a reference sequence, all isolates were similar, having the same R variant SNP profile with three substitutions compared to ΦSLT. This SNP profile is associated with the ΦSa2USA phage.

lukF-PV expression is shown in [Figure 3](#pone-0043037-g003){ref-type="fig"} and was measured to determine if there was a consistent expression profile across different ST93 strains. As expected, ST93 isolates which did not contain *lukS*-*PV/lukF*-*PV* did not express LukF-PV. However, there were three isolates (SAPCRGH95 isolated in NSW, SAPAH21 isolated in Vic, and 15587 isolated in WA) which were PVL positive by array hybridization and PCR but did not express LukF-PV indicating that there may be regulatory differences such as an *agr* defect in these isolates to account for the absence of LukF-PV. All other isolates produced LukF-PV, with expression levels similar between most strains.

![Relative LukF-PV expression in ST93 isolates.\
All isolates were tested for LukF-PV expression using western blot and LukF-PV specific antibody. Results are expressed as optical density of test strain relative to a 50 µg control of rLukF-PV that was run on every gel. All experiments were performed with multiple replicates and mean and range is shown. Positive control, rLUKF-PV; negative control, RN4220.](pone.0043037.g003){#pone-0043037-g003}

*Dru* Typing {#s3d}
------------

Six *dru* types were identified ([Table 1](#pone-0043037-t001){ref-type="table"}). The majority of isolates (35/45) were dt10 (33 dt10a, 1 dt10 g and 1 dt10i). The remaining nine SCC*mec* type IVa \[2B\] isolates were *dru* type dt4d (three isolates) and dt3b (6 isolates). The SCC*mec* type V \[5C2&5\] isolate (20198) was dt11i. The MST algorithm clustered the six *dru* types into three significantly different groups; dt10, dt4d plus dt3b, and dt11 ([Figure 4](#pone-0043037-g004){ref-type="fig"}). This suggests the SCC*mec* element may have been acquired on at least three occasions by ST93.

![Minimum spanning tree (MST) of the six ST93 *dru* types.\
Cluster analysis was performed using the Polymorphic VNTR plug-in tool of the BioNumerics program. *dru* types separated by an MST distance of ≤1 (i.e., if they were ≥98% similar) were considered closely related and assigned to the same cluster. Pulsed-field gel electrophoresis (PFGE) pulsotypes and *spa* types are recorded for each *dru* type.](pone.0043037.g004){#pone-0043037-g004}

Discussion {#s4}
==========

CA-MRSA is thought to emerge when a locally prevalent strain of methicillin susceptible *S. aureus* (MSSA) acquires a SCC*mec* element and utilizes mobile genetic elements and single nucleotide polymorphisms to establish local and geographic niches [@pone.0043037-Kennedy1]. Although the vertical and horizontal transmission of SCC*mec* elements into *S. aureus* has occurred on multiple occasions in the Australian community only a small number of clones have successfully found an ecological niche to predominate over other CA-MRSA clones [@pone.0043037-Coombs4]. PVL-positive ST93-IV \[2B\] is one such clone, and since 2000 has been reported across Australia and is responsible for the increasing prevalence of CA-MRSA infections nationwide [@pone.0043037-Coombs1].

Conflicting hypotheses have been proposed to explain the molecular evolution of ST93-MRSA. In 2008 Munckhof and colleagues found little genetic diversity within ST93-IV \[2B\] suggesting it arose from one PVL-positive binary subtype of ST93 MSSA after the acquisition of SCC*mec* [@pone.0043037-Munckhof2]. However in 2009 Tong and colleagues identified multiple *spa* types in ST93-MRSA and ST93-MSSA and proposed their data supported an early acquisition of SCC*mec* with subsequent rearrangement of the *spa* sequence or multiple independent acquisitions of SCC*mec* and coexistence of MSSA and MRSA versions of the same lineage [@pone.0043037-Tong1]. Although seven *spa* types were described in this study, cluster analysis of the seven *spa* sequences using the Spa typing plug-in tool of the BioNumerics software program shows six of the *spa* types are closely related and can be assigned to a single cluster (data not shown).

Unlike the Tong study, which examined the *spa* types of geographically localized ST93 *S aureus* collected over a short period, the current study examined ST93 *S aureus* isolated across Australia over sixteen years using a variety of molecular tools, providing greater power to detect unique evolutionary events in geographically diverse regions.

Prior to the isolation of ST93-IV \[2B\], *S aureus* surveillance screening of aboriginal people living in 11 remote Western Australian communities identified ST93 as the most prevalent MSSA lineage [@pone.0043037-OBrien1]. Although located in three geographically distant regions of WA, the ST93-MSSA examined from these communities, (W17S isolated in 1995, Y113S in 1996 and C229T and N126W in 2003, and) exhibit limited diversity within their PFGE patterns, *spa* types and microarray DNA profiles. Their two *spa* types, t202 \[3 isolates ("PFGE C")\] and t5767 ("PFGE A") are closely related and are assigned to the same cluster. The microarray DNA profiles for the two ST93-MSSA isolated in the Northern Territory in 1992 (WBG7735 and WBG7762) are homogeneous with the four WA remote community ST-93 MSSA. In addition their PFGE patterns are either identical ("PFGE A") or 90% related ("PFGE B"), and their *spa* types, t4699 and t4178, are assigned to the same cluster. The DNA microarray profiles for the five ST93-MSSA, (9506160A, 9509712N, 9524093R, 9525206A and 9529120L) isolated in the state's capital, Perth in 2008 (located 700--2000 km from the remote communities and over 3,000 km from the Northern Territory border) are also homogeneous with the Western Australian remote community strains. The PFGE pattern for these isolates is "PFGE A". The *spa* types for four of these strains are t202 (3 isolates) and t5767. The *spa* type for 9509712N (t6485) cannot be assigned to the same cluster. The PFGE patterns, *spa* types and microarray DNA profiles for the MSSA isolated on the Australian eastern seaboard (UQ40-- Queensland in 2008 and DP2039-- Victoria in 2007) are identical to three Perth ST93-MSSA-t202 isolates.

As shown in [Figure 1](#pone-0043037-g001){ref-type="fig"} the MRSA isolates are ≥80% related by PFGE with the majority of isolates falling into pulsotype D. Similar to the MSSA pulsotypes, pulsotype D was dispersed throughout Australia over the eight years. Although rearrangement of the *spa* sequence has occurred several times, the PFGE patterns and microarray DNA profiles of the 13 ST-93 MSSA isolates suggests the ST93 core and accessory genome is very stable. All carry the PVL-encoding phage ΦSa2USA and their *lukS*-*PV/lukF*-*PV* genes have the same R variant SNP profile. The isolates produce similar expression levels of LukF-PV with no apparent relationship between subtype and PVL expression. The emergence of five different *spa* types, albeit four types assigned to the same cluster, suggests ST93-MSSA emerged some time ago from a common *spa* type. As the *spa* sequences are similar it is not possible to predict the ancestral strain; however one strain, ST93-MSSA-t202, predominates and has successfully disseminated across Australia.

Like ST93-MSSA, ST93-MRSA has multiple *spa* types; including the closely related t202 and t4178, identified in ST93-MSSA, t1811 and t6487, all of which are assigned to the same cluster. t202 has the largest number of isolates; 42 of the 45 ST93-MRSA. SCC*mec* and *dru* typing indicates the SCC*mec* element has been acquired by ST93-MRSA-t202 on at least three occasions; dt10 (SCC*mec* type IVa \[2B\]), dt3b/dt4d (SCC*mec* type IVa \[2B\]) and dt11i (SCC*mec* type V \[5C&5\]). Unlike ST93-IVa \[2B\]-t202, ST93-V \[5C&5\]-t202 does not carry the *lukS-PV*/*lukF*-*PV* genes. The PVL-negative ST93-IVa \[2B\]-t1811 isolate may have arisen by independent acquisition of SCC*mec* IVa \[2B\] or by the subsequent rearrangement of the *spa* sequence.

As for ST93-MSSA, the PFGE patterns and microarray DNA profiles of the 45 ST-93 MRSA isolates suggests the ST93 core and accessory genome is stable. Forty three of the 45 isolates carry the PVL-encoding phage ΦSa2USA. The *lukS*-*PV/lukF*-*PV* genes have the same R variant SNP profile and produce similar expression levels of LukF-PV as reported in ST93-MSSA.

Apart from the *ermC* gene which was identified in several early ST93-MSSA and ST93-MRSA isolates, ST93 *S. aureus* initially carried few antibiotic resistance elements. However since 2008, in addition to *mecA* and *ermC*, some isolates of ST93-MRSA have acquired the *msr(A)* and *tetK* resistance genes. Although the *dfrA* gene was not detected by the microarray DNA, SAPWH53 is phenotypically trimethoprim resistant (presumably due to an alternative trimethoprim resistance gene or a different *dfrA* allele). In addition, the quaternary ammonium compound resistance protein C gene *qacC* is carried by two isolates. The acquisition of several resistance genes by an epidemic PVL-positive CA-MRSA clone is not unique to ST93-IV \[2B\]. The USA300 clone (ST8-IV \[2B\]), initially resistant only to semi-synthetic penicillins and macrolides, is now, frequently resistant to other antimicrobial agents including clindamycin, tetracycline, mupirocin, and the fluoroquinolones; occasionally resistant to gentamicin and trimethoprim-sulfamethoxazole, and may have reduced susceptibility to daptomycin [@pone.0043037-Tenover2].

Single strain outbreaks of ST93-IV \[2B\] have not been reported in Australian hospitals, however as has been reported in United States hospitals with USA300 [@pone.0043037-Tenover3], ST93-IV \[2B\] has become a major cause of healthcare-associated/onset infection. In 2008 Munckhof and colleagues reported nearly three quarters of nmMRSA infections in their hospital-based study were healthcare associated, of which ST93-IV \[2B\] predominated [@pone.0043037-Munckhof2].

Conclusion {#s4a}
----------

This study has demonstrated that although multiple rearrangements of the *spa* sequence have occurred, the core genome in ST93 *S. aureus* is very stable. Since 2008 PVL-positive ST93-MSSA-t202 has become the predominant ST93-MSSA across Australia. We have shown the emergence of ST93-MRSA has been due to independent acquisitions of different *dru*-defined type IV and type V SCC*mec* elements in several *spa-*defined ST93-MSSA backgrounds. Rearrangement of the *spa* sequence in ST93-MRSA has subsequently occurred in some of these strains. Although several ST93-MRSA strains have been identified in this study, little genetic diversity was identified for most MRSA isolates, with PVL-positive ST93-IVa \[2B\]-t202-dt10 predominant across Australia. However to determine if ST93-IVa \[2B\] t202-dt10 has arisen from one PVL-positive ST93-MSSA-t202, or by independent acquisitions of SCCmec-IVa \[2B\]-dt10 into multiple PVL-positive ST93-MSSA-t202 strains will require whole genomic sequencing of the isolates. Furthermore, comparative genomic sequencing may further enhance our understanding of the molecular basis for the emergence and increased virulence of ST93 CA-MRSA. At a time when this clone is acquiring additional resistance genes and an increased potential for infections in the healthcare setting, understanding the means for SCC*mec* acquisition, virulence determinants and transmission dynamics is crucial if we are to prevent this clone from becoming established in hospitals.
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